GMGuo-Xin Mao

Guo-Xin Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guo-Xin Mao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Hua Wang

    Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China

    2 shared publications
  • Shuyun Yang

    Department of Pathology, Nantong University Cancer Hospital, Nantong University, Nantong, 226001, Jiangsu, China.

    2 shared publications
  • Chao Wang

    Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, China

    1 shared publication
  • Chun-Hui Zhang

    Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China

    1 shared publication
  • Chunhui Zhang

    Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, China

    1 shared publication
  • Jia Zhu

    Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, Nantong, China

    1 shared publication

Latest Publications

  • The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines

    by Ying-Ying Wang, Xiao-Ling Gu, Chao Wang, Hua Wang, Qi-Chao Ni, Chun-Hui Zhang, Xia-Fei Yu, Li-Yi Yang, Zhi-Xian He, Guo-Xin Mao, et al.

    Far-upstream element (FUSE)-binding protein 2 (FBP2) was a member of single-stranded DNA-binding protein family; it played an important role in regulating transcription and post-transcription and is involved in the regulation of C-MYC gene expression in liver tumors. However, the role of FBP2 in breast cancer and its mechanism has not been studied yet. Here, we discovered that FBP2 was up-regulated in breast cancer tissues and breast cancer cell lines. Moreover, immunohistochemistry analysis demonstrated that up-regulated FBP2 was highly associated with tumor grade, Ki-67, and poor prognosis, which was an independent prognostic factor for survival of breast cancer patients. At the cellular level, we found that FBP2 was correlated with cell cycle progression by accelerating G1/S transition, and knockdown of FBP2 could weaken cell proliferation, anchorage-independent cell growth, while enhancing the sensitivity of breast cancer cells to doxorubicin. More importantly, we found that activation of PI3K/AKT pathway could phosphorylate FBP2, and then make FBP2 shuttle from cytoplasm into the nucleus, which was the main mechanism of breast cancer cell proliferation and drug resistance. Taken together, our findings supported the notion that FBP2 might via PI3K/AKT pathway influence breast cancer progression and drug resistance, which might provide a new target for the design of anti-cancer drugs for breast cancer patients.


  • Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer

    by Xiaoling Gu, Yingying Wang, Hua Wang, Qichao Ni, Chunhui Zhang, Jia Zhu, Wei Huang, Pan Xu, Guoxin Mao, Shuyun Yang

    PFTK1 was a cell division cycle 2-related serine/threonine protein kinase, which was up-regulated in breast cancer tissues and breast cancer lines. And up-regulated PFTK1 was highly associated with grade, axillary lymph node status, and Ki-67. Moreover, Kaplan–Meier curve showed that up-regulated PFTK1 was related to the poor breast carcinoma patients’ overall survival. Here, we first discovered and confirmed that cyclin B was a new interacting protein of PFTK1, and the complex might increase the amount of DVL2, which triggers Wnt/β-catenin signaling pathway. Furthermore, knockdown of PFTK1 attenuated cell proliferation, anchorage-independent cell growth, and cell migration and invasion by inhibiting the transcriptional activation of β-catenin for cyclin D1, MMP9, and HEF1, whereas exogenous expression of PFTK1 might promote MDA-MB-231 cells proliferation, migration, and invasion via promoting PFTK1–DVL2–β-catenin axis. Our findings supported the notion that up-regulated PFTK1 might promote breast cancer progression and metastasis by activating Wnt signaling pathway through the PFTK1–DVL2–β-catenin axis.